Long-Term Effectiveness of XEN 45 Gel-Stent in Open-Angle Glaucoma Patients
Purpose: To assess the effectiveness of XEN45, either alone or in combination with phacoemulsification, in open-angle glaucoma (OAG) patients in clinical practice.Methods: Retrospective and single-center study conducted on OAG patients who underwent XEN45 implant, either alone or in combination with...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| Repositorio: | r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| OAI Identifier: | oai:isabial.fundanetsuite.com:p9623 |
| Acceso en línea: | https://isabial.portalinvestigacion.com/publicaciones9623 |
| Access Level: | acceso abierto |
| Palabra clave: | open -angle glaucoma MIGS XEN45 intraocular pressure learning -curve |
| Sumario: | Purpose: To assess the effectiveness of XEN45, either alone or in combination with phacoemulsification, in open-angle glaucoma (OAG) patients in clinical practice.Methods: Retrospective and single-center study conducted on OAG patients who underwent XEN45 implant, either alone or in combination with cataract surgery. We compared the clinical outcomes of the eyes of thosewho underwent XEN-solo versus those who underwent XEN+Phacoemulsification. The primary endpoint was the mean change in intraocular pressure (IOP) from baseline to the last follow-up visit.Results: A total of 154 eyes, 37 (24.0%) eyes that underwent XEN-solo and 117 (76.0%) eyes that underwent XEN +Phacoemulsification, were included. The mean preoperative IOP was significantly lowered from 19.1 +/- 5.0 mmHg to 14.9 +/- 3.8 mmHg at month-36, p<0.0001. Preoperative IOP was significantly lowered from 21.2 +/- 6.2 mmHg and 18.4 +/- 4.3 mmHg to 14.3 +/- 4.0 mm Hg and 15.2 +/- 3.7 mmHg at month-36 in the XEN-solo and XEN+Phacoemulsification groups, p<0.0004 and p=0.0009; with no significant differences between them. In the overall study population, the mean number of antiglaucoma medications was significantly reduced from 2.1 +/- 0.8 to 0.2 +/- 0.6, p<0.0001. There were no significant differences in the proportion of eyes with a final IOP <= 14 mmHg and <= 16 mmHg between XEN-solo and XEN+Phaco groups (p=0.8406 and 0.04970, respectively). Thirty-six (23.4%) eyes required a needling procedure.Conclusion: XEN implant significantly lowered IOP and reduced the need of ocular hypotensive medication, while maintaining a good safety profile. Beyond week-1, there were no significant differences in IOP lowering between XEN-solo and XEN +Phacoemulsification groups. |
|---|